

# GLOBAL MARKETS FOR VACCINE TECHNOLOGIES



PHM014E  
July 2013

Shalini Shahani Dewan  
*Project Analyst*

ISBN: 1-56965-480-8

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	4
RELATED BCC RESEARCH REPORTS	4
BCC ONLINE SERVICES	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH 2017 (\$ MILLIONS)</i>	9
<i>SUMMARY FIGURE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, 2010-2017 (\$ MILLIONS)</i>	9
CHAPTER 3 OVERVIEW	11
DEFINITION OF A VACCINE	11
DEFINITION OF IMMUNITY	11
ACTIVE	11
PASSIVE	11
HOW VACCINES WORK	12
IMPORTANCE OF VACCINES	12
HISTORY OF VACCINES	12
<i>TABLE 1 HISTORY OF VACCINES</i>	12
TYPES OF VACCINES	14
ATTENUATED (LIVE) VACCINES	14
Types of Attenuated (Live) Vaccines	15
<i>TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES</i>	15
Advantages and Disadvantages of Attenuated (Live) Vaccines	16
<i>TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES</i>	16
INACTIVATED (KILLED) VACCINES	17
Types of Inactivated (Killed) Vaccines	17
<i>TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES</i>	17
Advantages and Disadvantages of Inactivated (Killed) Vaccines	18
<i>TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES</i>	18
TOXOID VACCINES	18
Types of Toxoid Vaccines	19
<i>TABLE 6 TYPES OF TOXOID VACCINES</i>	19
Advantages and Disadvantages of Toxoid Vaccines	19
<i>TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES</i>	19
SUBUNIT VACCINES	20
Types of Subunit Vaccines	20
<i>TABLE 8 TYPES OF SUBUNIT VACCINES</i>	20

<b>TOPIC</b>	<b>PAGE NO.</b>
Advantages and Disadvantages of Subunit Vaccines	21
<i>TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES</i>	21
CONJUGATE VACCINES	21
Types of Conjugate Vaccines	22
<i>TABLE 10 TYPES OF CONJUGATE VACCINES</i>	22
Advantages and Disadvantages of Conjugate Vaccines	22
<i>TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES</i>	22
RECOMBINANT VECTOR VACCINES	22
Types of Recombinant Vector Vaccines	23
<i>TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES</i>	23
Advantages and Disadvantages of Recombinant Vector Vaccines	24
<i>TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES</i>	24
DNA VACCINES	24
Types of DNA Vaccines	25
<i>TABLE 14 TYPES OF DNA VACCINES</i>	25
Advantages and Disadvantages of DNA vaccines	25
<i>TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES</i>	25
<i>INFECTIOUS DISEASES PREVENTABLE BY VACCINES</i>	26
HUMAN DISEASES	26
Viral Diseases	26
<i>TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES</i>	27
Bacterial Diseases	28
<i>TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES</i>	29
ANIMAL DISEASES	31
Food Producing Animals	32
<i>TABLE 18 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING ANIMALS</i>	32
Companion Animals	34
<i>TABLE 19 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION ANIMALS</i>	35
Other Animals	35
<i>TABLE 20 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS</i>	36
<i>TABLE 21 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS</i>	37
CHAPTER 4 REGULATORY ASPECTS	44
REGULATORY ASPECTS	44
<i>TABLE 22 NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS</i>	44
<i>TABLE 23 REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012</i>	46
<i>TABLE 24 NEWLY APPROVED VACCINES, 2010 THROUGH 2012</i>	51
<i>TABLE 25 GLOBAL VACCINE RECALLS, 2010 THROUGH 2012</i>	52
<i>REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE DISEASE PRODUCTS</i>	53
CHAPTER 5 PREVALENCE	56
INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES	56
REGIONAL DATA	56
<i>TABLE 26 REPORTED INCIDENCE DATA OF HUMAN DISEASES (NO.)</i>	56

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 27 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES (%)</i>	57
GLOBAL DATA	58
<i>TABLE 28 REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES WORLDWIDE, 2010 AND 2011 (NO.)</i>	58
<i>TABLE 29 IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN DISEASES WORLDWIDE, 2010 AND 2011 (%)</i>	59
GLOBAL IMMUNIZATION UPTAKE DATA	59
<i>TABLE 30 UPTAKE OF NEW AND UNDERUSED VACCINES, 2011 (NO.)</i>	59
GLOBAL DEATHS DUE TO VACCINE-PREVENTABLE DISEASES	60
<i>TABLE 31 DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH VACCINES, 2011 (NO.)</i>	60
<i>TABLE 32 ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020 (MILLIONS)</i>	61
CHAPTER 6 NEW DEVELOPMENTS	63
NEW DEVELOPMENTS	63
<i>TABLE 33 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012</i>	64
<i>TABLE 34 ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, 2010-2012</i>	71
NEW COLLABORATIVE TRIALS	72
CHAPTER 7 GLOBAL MARKETS FOR HUMAN AND ANIMAL VACCINES	75
VACCINE MARKET BY CATEGORY	76
MARKET OVERVIEW	76
Recent Developments in Animal Vaccines	77
MARKET REVENUE	77
<i>TABLE 35 GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017 (\$ MILLIONS)</i>	78
<i>FIGURE 1 GLOBAL SALES OF VACCINES BY CATEGORY, 2010-2017 (\$ MILLIONS)</i>	78
MARKET SHARE	78
<i>TABLE 36 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%)</i>	79
<i>FIGURE 2 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%)</i>	79
MARKET BY TYPE	79
MARKET FOR HUMAN VACCINES	79
Market Overview	80
Market Revenue	82
<i>TABLE 37 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	82
<i>FIGURE 3 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)</i>	82
Market Share	83
<i>TABLE 38 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)</i>	83
<i>FIGURE 4 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)</i>	84
MARKET FOR ANIMAL HEALTH PRODUCTS	84
Market Overview	85
Market Revenue	86
<i>TABLE 39 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	86

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 5 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)</i>	86
Market Share	87
<i>TABLE 40 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)</i>	87
<i>FIGURE 6 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)</i>	87
MARKET BY REGION	88
MARKET OVERVIEW	88
Human Vaccines	89
Animal Vaccines	89
MARKET REVENUE	90
<i>TABLE 41 GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	90
<i>FIGURE 7 GLOBAL SALES OF VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	90
MARKET SHARE	91
<i>TABLE 42 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%)</i>	91
<i>FIGURE 8 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%)</i>	91
MARKET BY APPLICATION	92
HUMAN VACCINES	92
MARKET OVERVIEW	93
MARKET REVENUE	94
<i>TABLE 43 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	94
<i>FIGURE 9 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, 2010-2017 (\$ MILLIONS)</i>	95
MARKET SHARE BY APPLICATION	95
<i>TABLE 44 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)</i>	96
<i>FIGURE 10 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)</i>	96
MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION	96
<i>TABLE 45 MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011 (%)</i>	97
CHAPTER 8 MARKET ANALYSIS OF HUMAN VACCINES	99
MARKET BY TYPE	99
MARKET OVERVIEW	99
MARKET REVENUE	100
<i>TABLE 46 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	101
<i>FIGURE 11 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)</i>	102
MARKET SHARE	102
<i>TABLE 47 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)</i>	102
<i>FIGURE 12 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)</i>	103
MARKET BY REGION	103
MARKET OVERVIEW	103
MARKET REVENUE	104
<i>TABLE 48 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	105

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 13 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	105
MARKET SHARE	105
<i>TABLE 49 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%)</i>	106
<i>FIGURE 14 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%)</i>	106
Regional Markets for Attenuated (Live) Vaccines	106
Market Overview	107
Market Revenue	108
<i>TABLE 50 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	108
<i>FIGURE 15 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	108
Regional Markets for Inactivated Vaccines	109
Market Overview	109
Market Revenue	110
<i>TABLE 51 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	111
<i>FIGURE 16 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	111
Regional Markets for Conjugate Vaccines	111
Market Overview	112
Market Revenue	112
<i>TABLE 52 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	113
<i>FIGURE 17 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	113
Regional Markets for rDNA/DNA Vaccines	114
Market Overview	114
Market Revenue	115
<i>TABLE 53 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	115
<i>FIGURE 18 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	116
Regional Markets for Subunit Vaccines	116
Market Overview	116
Market Revenue	117
<i>TABLE 54 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	118
<i>FIGURE 19 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	118
Regional Markets for Toxoid Vaccines	118
Market Overview	119
Market Revenue	119
<i>TABLE 55 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	119
<i>FIGURE 20 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	120
Regional Markets for Other/Combination Vaccines	120
Market Overview	120
Market Revenue	121

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 56 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	121
<i>FIGURE 21 global market for other/combination vaccines by region, 2010-2017 (\$ MILLIONS)</i>	121
MARKET BY APPLICATION	122
PROPHYLACTIC VACCINES	122
THERAPEUTIC VACCINES	123
<i>TABLE 57 HUMAN VACCINES BASED ON MICROORGANISM</i>	123
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES	124
Meningococcal	124
Pneumococcal Diseases	125
Noninvasive Pneumococcal Diseases	125
Invasive Pneumococcal Diseases	125
Market Revenue	126
<i>TABLE 58 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017 (\$ MILLIONS)</i>	126
<i>FIGURE 22 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES MARKET, 2010-2017 (\$ MILLIONS)</i>	127
Market Share	127
<i>TABLE 59 MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/PNEUMOCOCCAL VACCINES, 2011 (%)</i>	127
INFLUENZA (SEASONAL AND PANDEMIC) DISEASES	128
Market Revenue	129
<i>TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2017 (\$ MILLIONS)</i>	130
<i>FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2010-2017 (\$ MILLIONS)</i>	130
Market Share	130
<i>TABLE 61 MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011 (%)</i>	131
PEDIATRIC POLIO/PERTUSSIS/HIB	131
Market Revenue	133
<i>TABLE 62 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, THROUGH 2017 (\$ MILLIONS)</i>	133
<i>FIGURE 24 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2010-2017 (\$ MILLIONS)</i>	133
Market Share	134
<i>TABLE 63 MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2011 (%)</i>	134
ADULT/ADOLESCENT BOOSTER VACCINES	135
Market Revenue	135
<i>TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES MARKET, THROUGH 2017 (\$ MILLIONS)</i>	136
<i>FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES MARKET, 2010-2017 (\$ MILLIONS)</i>	136
Market Share	137
<i>TABLE 65 MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2011 (%)</i>	137
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES	137
Market Revenue	139

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 66 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2017 (\$ MILLIONS)</i>	139
<i>FIGURE 26 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2010-2017 (\$ MILLIONS)</i>	140
Market Share	140
<i>TABLE 67 MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2011 (%)</i>	141
HPV DISEASE	141
Market Revenue	142
<i>TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017 (\$ MILLIONS)</i>	142
<i>FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN HPV, 2010-2017 (\$ MILLIONS)</i>	142
Market Share	143
<i>TABLE 69 MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011 (%)</i>	143
ROTAVIRUS DISEASE	143
Market Revenue	144
<i>TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH 2017 (\$ MILLIONS)</i>	144
<i>FIGURE 28 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, 2010-2017 (\$ MILLIONS)</i>	144
Market Share	145
<i>TABLE 71 MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011 (%)</i>	145
OTHER DISEASES	145
Recent Developments	146
Market Revenue	147
<i>TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2017 (\$ MILLIONS)</i>	147
<i>FIGURE 29 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2010-2017 (\$ MILLIONS)</i>	147
Market Share	148
<i>TABLE 73 MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2011 (%)</i>	149
MARKET SHARE OF APPLICATIONS	149
<i>TABLE 74 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)</i>	150
<i>FIGURE 30 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)</i>	150
INDUSTRY STRUCTURE	150
MARKET LEADERS	151
<i>TABLE 75 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES</i>	151
MARKET SHARES	157
<i>TABLE 76 MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE SALES, 2011 (%)</i>	157
<i>FIGURE 31 MANUFACTURERS/PROCESSORS' MARKET SHARES OF HUMAN VACCINE SALES, 2011 (%)</i>	158
<b>CHAPTER 9 MARKET ANALYSIS OF ANIMAL VACCINES</b>	160
MARKET OVERVIEW	160
MARKET REVENUE	161



<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 77 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2010-2012 (\$ MILLIONS)</i>	162
<i>FIGURE 32 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2010-2012 (\$ MILLIONS)</i>	162
ANIMAL VACCINES	163
MARKET BY TYPE	164
<i>TABLE 78 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	165
<i>FIGURE 33 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)</i>	165
Vaccines Used in Food Producing Animals	166
Market Overview	166
Market Revenue	167
<i>TABLE 79 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	167
<i>FIGURE 34 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2010-2017 (\$ MILLIONS)</i>	167
Companion Animal Vaccines	168
Market Overview	168
Market Revenue	169
<i>TABLE 80 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	169
<i>FIGURE 35 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2010-2017 (\$ MILLIONS)</i>	170
Other Animal Vaccines	170
Market Overview	170
Market Revenue	171
<i>TABLE 81 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	171
<i>FIGURE 36 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	171
Market Share	172
<i>TABLE 82 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)</i>	172
<i>FIGURE 37 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)</i>	172
MARKET BY REGION	173
Market Overview	173
Market Revenue	174
<i>TABLE 83 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	175
<i>FIGURE 38 GLOBAL SALES OF ANIMAL VACCINES BY REGION, 2010-2017 (\$ MILLIONS)</i>	175
Market Share	175
<i>TABLE 84 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%)</i>	176
<i>FIGURE 39 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%)</i>	176
INDUSTRY STRUCTURE	176
MARKET LEADERS	176
<i>TABLE 85 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES</i>	176
MARKET SHARES	178

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 86 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE SALES, 2011 (%)</i>	179
<i>FIGURE 40 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE SALES, 2011 (%)</i>	180
CHAPTER 10 PATENT ANALYSIS	182
PATENTS BY YEAR	182
<i>TABLE 87 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR, 2010-2012 (NO.)</i>	183
<i>FIGURE 41 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR, 2010-2012 (NO.)</i>	183
PATENTS BY VACCINE TYPE	183
<i>TABLE 88 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE, 2010-2012 (NO.)</i>	184
<i>FIGURE 42 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE, 2010-2012 (NO.)</i>	184
PATENTS BY ASSIGNEE'S COUNTRY	185
ATTENUATED (LIVE) VACCINES	185
<i>TABLE 89 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	185
<i>FIGURE 43 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	185
<i>TABLE 90 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%)</i>	186
<i>FIGURE 44 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	187
INACTIVATED (KILLED) VACCINES	187
<i>TABLE 91 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	188
<i>FIGURE 45 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	189
<i>TABLE 92 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%)</i>	189
<i>FIGURE 46 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	190
TOXOID VACCINES	190
<i>TABLE 93 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	190
<i>FIGURE 47 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	190
<i>TABLE 94 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	191
<i>FIGURE 48 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	191
SUBUNIT VACCINES	192
<i>TABLE 95 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	192
<i>FIGURE 49 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	193
<i>TABLE 96 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	193

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 50 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	193
CONJUGATE VACCINES	194
<i>TABLE 97 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	194
<i>FIGURE 51 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	195
<i>TABLE 98 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	195
<i>FIGURE 52 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	196
RECOMBINANT/RDNA/DNA VACCINES	196
<i>TABLE 99 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	196
<i>FIGURE 53 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	197
<i>TABLE 100 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	198
<i>FIGURE 54 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	199
OTHER/COMBINATION VACCINES	199
<i>TABLE 101 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	199
<i>FIGURE 55 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)</i>	200
<i>TABLE 102 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	201
<i>FIGURE 56 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)</i>	202
PATENTS BY COMPANY	202
ATTENUATED (LIVE) VACCINES	202
<i>TABLE 103 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY COMPANY, 2010-2012 (NO.)</i>	202
<i>FIGURE 57 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY COMPANY, 2010-2012 (NO.)</i>	203
INACTIVATED (KILLED) VACCINES	204
<i>TABLE 104 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY COMPANY, 2010-2012 (NO.)</i>	204
<i>FIGURE 58 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY COMPANY, 2010-2012 (NO.)</i>	204
SUBUNIT VACCINES	205
<i>TABLE 105 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY, 2010-2012 (NO.)</i>	205
<i>FIGURE 59 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY, 2010-2012 (NO.)</i>	206
CONJUGATE VACCINES	206
<i>TABLE 106 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY, 2010-2012 (NO.)</i>	206
<i>FIGURE 60 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY, 2010-2012 (NO.)</i>	207
RECOMBINANT/RDNA/DNA VACCINES	207

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 107 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY COMPANY, 2010-2012 (NO.)</i>	208
<i>FIGURE 61 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY COMPANY, 2010-2012 (NO.)</i>	208
OTHER/COMBINATION VACCINES	209
<i>TABLE 108 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY COMPANY, 2010-2012 (NO.)</i>	209
<i>FIGURE 62 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY COMPANY, 2010-2012 (NO.)</i>	210
PATENTS BY ASSIGNEE	211
ATTENUATED (LIVE) VACCINES	211
<i>TABLE 109 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	212
<i>FIGURE 63 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	212
INACTIVATED (KILLED) VACCINES	212
<i>TABLE 110 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	213
<i>FIGURE 64 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	213
TOXOID VACCINES	213
<i>TABLE 111 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	214
<i>FIGURE 65 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	214
SUBUNIT VACCINES	214
<i>TABLE 112 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	215
<i>FIGURE 66 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	215
CONJUGATE VACCINES	215
<i>TABLE 113 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	216
<i>FIGURE 67 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	216
RECOMBINANT/RDNA/DNA VACCINES	216
<i>TABLE 114 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	217
<i>FIGURE 68 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	217
OTHER/COMBINATION VACCINES	217
<i>TABLE 115 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	218
<i>FIGURE 69 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)</i>	218
CHAPTER 11 CURRENT SITUATION	220
ORGANIZATIONS DEDICATED TO GLOBAL IMMUNIZATIONS FOR HUMANS	220
GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS)	220
GIVS Aims-2006 through 2012	221
GIVS Goals by 2015 or earlier	221

<b>TOPIC</b>	<b>PAGE NO.</b>
GIVS Strategies	221
GIVS Global Immunization Progress	221
GLOBAL VACCINE ACTION PLAN (GVAP)	222
Six Guiding Principles of GVAP	222
GVAP Goals-2011 through 2020	222
<i>TABLE 116 GVAP GOAL LEVEL TARGETS</i>	223
GVAP Strategic Objectives-2011 through 2010	223
THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNISATION (GAVI)	224
GAVI Potential Forecast-2011 through 2015	224
GAVI Focus	225
GAVI Progress	225
FUNDING AND CHALLENGES	225
<i>UPDATE ON VACCINE-PREVENTABLE DISEASES IN HUMANS</i>	226
WHO PREQUALIFIED MANUFACTURERS OF HUMAN VACCINES	226
<i>TABLE 117 WHO-PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2012</i>	227
FUTURE VACCINE PRIORITIZATION	227
<i>TABLE 118 VACCINE PRIORITIZATION, 2013-2014</i>	228
CURRENT AND FUTURE (PROPOSED) VACCINE ACHIEVEMENTS AND CHALLENGES	229
<i>TABLE 119 VACCINE ACHIEVEMENTS AND CHALLENGES THROUGH 2012</i>	230
WHO VACCINE RESEARCH AND PROGRESS	232
<i>TABLE 120 WHO VACCINE RESEARCH AND PROGRESS</i>	232
NEW VACCINE TECHNOLOGIES AND PLATFORMS	232
PROGRESS IN HUMAN VACCINES	233
Peptide Vaccines	233
New Molecular Technique to Control and Develop Malaria Vaccine	233
Hydrogen Peroxide-Based Vaccine Platform	233
PROGRESS IN ANIMAL VACCINES	234
FACTORS AFFECTING THE VACCINE MARKET	234
HIGH PRICES OF NEWER VACCINES	234
LACK OR RESEARCH OPPORTUNITIES	234
WEAK LOCAL HEALTH CENTERS	235
ISSUES WITH MIDDLE INCOME COUNTRIES	235
HURDLES FOR NEW ENTRANTS	235
CURRENT DRIVERS OF THE VACCINE MARKET	235
DRIVERS OF THE MARKET FOR HUMAN VACCINES	235
DRIVERS OF THE MARKET FOR ANIMAL VACCINES	236
ACQUISITIONS/COLLABORATIONS	236
CHAPTER 12 COMPANY PROFILES	239
ABBOTT LABORATORIES	239
ADVAXIS	239
AERAS GLOBAL	240
ALPHAVAX INC.	241
ASTELLAS PHARMA INC.	241
ASTRAZENECA PLC	242
BAXTER INTERNATIONAL INC.	243

<b>TOPIC</b>	<b>PAGE NO.</b>
BAYER HEALTHCARE ANIMAL HEALTH	244
BHARAT BIOTECH INTERNATIONAL LTD.	245
BIOLOGICAL E. LTD.	246
BIO-MANGUINHOS	246
BIOPROPERTIES	247
BOEHRINGER INGELHEIM GMBH	247
BUL BIO-NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.)	248
CADILA HEALTHCARE LTD.	249
CEVA SANTE ANIMALE	249
CHINA NATIONAL BIOTEC GROUP (CNBG)	251
COLORADO SERUM CO.	252
CRUCCELL	252
CSL LTD.	254
ELANCO ANIMAL HEALTH	254
EMERGENT BIOSOLUTIONS INC.	255
FATRO SPA	256
GENVEC INC.	257
GEOVAX	258
GLAXOSMITHKLINE PLC	259
GREEN CROSS CORP.	260
HESKA CORP.	261
IMMUNE SOLUTIONS LTD.	261
INSTITUT PASTEUR DE DAKAR	262
INTERCELL AG	262
JAPAN BCG LABORATORY	264
LG LIFE SCIENCES	264
LOHMANN ANIMAL HEALTH INTERNATIONAL	265
MERCK & CO. INC.	266
MERIAL INC.	267
NIPPON BIOLOGICALS INC.	268
NOVARTIS AG	269
OKAIROS AG	270
PANACEA BIOTEC LTD.	271
PFENEX INC.	271
PFIZER	273
PROFECTUS BIOSCIENCES INC.	274
PT BIO FARMA	275
SANOFI PASTEUR	276
SERUM INSTITUTE OF INDIA LTD.	277
SHANTHA BIOTECHNICS LTD.	278
STATENS SERUM INSTITUT	279
VGX INTERNATIONAL INC.	279
VIRBAC	280
ZOETIS INC.	280
CHAPTER 13 APPENDIX I	284
ABBREVIATIONS	284

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH 2017 (\$ MILLIONS)	9
TABLE 1 HISTORY OF VACCINES	12
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES	15
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES	16
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES	17
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES	18
TABLE 6 TYPES OF TOXOID VACCINES	19
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES	19
TABLE 8 TYPES OF SUBUNIT VACCINES	20
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES	21
TABLE 10 TYPES OF CONJUGATE VACCINES	22
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES	22
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES	23
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES	24
TABLE 14 TYPES OF DNA VACCINES	25
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES	25
TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES	27
TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES	29
TABLE 18 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING ANIMALS	32
TABLE 19 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION ANIMALS	35
TABLE 20 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS	36
TABLE 21 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS	37
TABLE 22 NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS	44
TABLE 23 REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012	46
TABLE 24 NEWLY APPROVED VACCINES, 2010 THROUGH 2012	51
TABLE 25 GLOBAL VACCINE RECALLS, 2010 THROUGH 2012	52
TABLE 26 REPORTED INCIDENCE DATA OF HUMAN DISEASES (NO.)	56
TABLE 27 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES (%)	57
TABLE 28 REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES WORLDWIDE, 2010 AND 2011 (NO.)	58
TABLE 29 IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN DISEASES WORLDWIDE, 2010 AND 2011 (%)	59
TABLE 30 UPTAKE OF NEW AND UNDERUSED VACCINES, 2011 (NO.)	59
TABLE 31 DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH VACCINES, 2011 (NO.)	60
TABLE 32 ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020 (MILLIONS)	61
TABLE 33 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012	64
TABLE 34 ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, 2010-2012	71
TABLE 35 GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017 (\$ MILLIONS)	78
TABLE 36 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%)	79
TABLE 37 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)	82

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 38 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)	83
TABLE 39 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)	86
TABLE 40 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)	87
TABLE 41 GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	90
TABLE 42 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%)	91
TABLE 43 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017 (\$ MILLIONS)	94
TABLE 44 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)	96
TABLE 45 MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011 (%)	97
TABLE 46 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)	101
TABLE 47 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)	102
TABLE 48 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	105
TABLE 49 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%)	106
TABLE 50 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	108
TABLE 51 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	111
TABLE 52 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	113
TABLE 53 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	115
TABLE 54 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	118
TABLE 55 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	119
TABLE 56 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	121
TABLE 57 HUMAN VACCINES BASED ON MICROORGANISM	123
TABLE 58 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017 (\$ MILLIONS)	126
TABLE 59 MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/PNEUMOCOCCAL VACCINES, 2011 (%)	127
TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2017 (\$ MILLIONS)	130
TABLE 61 MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011 (%)	131
TABLE 62 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, THROUGH 2017 (\$ MILLIONS)	133
TABLE 63 MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2011 (%)	134
TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES MARKET, THROUGH 2017 (\$ MILLIONS)	136
TABLE 65 MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2011 (%)	137
TABLE 66 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2017 (\$ MILLIONS)	139



<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 67 MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2011 (%)	141
TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017 (\$ MILLIONS)	142
TABLE 69 MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011 (%)	143
TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH 2017 (\$ MILLIONS)	144
TABLE 71 MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011 (%)	145
TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2017 (\$ MILLIONS)	147
TABLE 73 MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2011 (%)	149
TABLE 74 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)	150
TABLE 75 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES	151
TABLE 76 MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE SALES, 2011 (%)	157
TABLE 77 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2010-2012 (\$ MILLIONS)	162
TABLE 78 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 (\$ MILLIONS)	165
TABLE 79 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2017 (\$ MILLIONS)	167
TABLE 80 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2017 (\$ MILLIONS)	169
TABLE 81 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	171
TABLE 82 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)	172
TABLE 83 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	175
TABLE 84 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%)	176
TABLE 85 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES	176
TABLE 86 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE SALES, 2011 (%)	179
TABLE 87 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR, 2010-2012 (NO.)	183
TABLE 88 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE, 2010-2012 (NO.)	184
TABLE 89 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	185
TABLE 90 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%)	186
TABLE 91 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	188
TABLE 92 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%)	189
TABLE 93 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	190
TABLE 94 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	191
TABLE 95 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	192

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 96 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	193
TABLE 97 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	194
TABLE 98 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	195
TABLE 99 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	196
TABLE 100 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	198
TABLE 101 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	199
TABLE 102 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	201
TABLE 103 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY COMPANY, 2010-2012 (NO.)	202
TABLE 104 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY COMPANY, 2010-2012 (NO.)	204
TABLE 105 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY, 2010-2012 (NO.)	205
TABLE 106 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY, 2010-2012 (NO.)	206
TABLE 107 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY COMPANY, 2010-2012 (NO.)	208
TABLE 108 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY COMPANY, 2010-2012 (NO.)	209
TABLE 109 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	212
TABLE 110 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	213
TABLE 111 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	214
TABLE 112 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	215
TABLE 113 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	216
TABLE 114 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	217
TABLE 115 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	218
TABLE 116 GVAP GOAL LEVEL TARGETS	223
TABLE 117 WHO-PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2012	227
TABLE 118 VACCINE PRIORITIZATION, 2013-2014	228
TABLE 119 VACCINE ACHIEVEMENTS AND CHALLENGES THROUGH 2012	230
TABLE 120 WHO VACCINE RESEARCH AND PROGRESS	232

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, 2010-2017 (\$ MILLIONS)	9
FIGURE 1 GLOBAL SALES OF VACCINES BY CATEGORY, 2010-2017 (\$ MILLIONS)	78
FIGURE 2 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%)	79
FIGURE 3 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)	82
FIGURE 4 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)	84
FIGURE 5 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)	86
FIGURE 6 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)	87
FIGURE 7 GLOBAL SALES OF VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	90
FIGURE 8 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%)	91
FIGURE 9 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, 2010-2017 (\$ MILLIONS)	95
FIGURE 10 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)	96
FIGURE 11 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)	102
FIGURE 12 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%)	103
FIGURE 13 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	105
FIGURE 14 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%)	106
FIGURE 15 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	108
FIGURE 16 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	111
FIGURE 17 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	113
FIGURE 18 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	116
FIGURE 19 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	118
FIGURE 20 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	120
FIGURE 21 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	121
FIGURE 22 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES MARKET, 2010-2017 (\$ MILLIONS)	127
FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2010-2017 (\$ MILLIONS)	130
FIGURE 24 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2010-2017 (\$ MILLIONS)	133
FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES MARKET, 2010-2017 (\$ MILLIONS)	136
FIGURE 26 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2010-2017 (\$ MILLIONS)	140
FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN HPV, 2010-2017 (\$ MILLIONS)	142
FIGURE 28 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, 2010-2017 (\$ MILLIONS)	144

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 29 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2010-2017 (\$ MILLIONS)	147
FIGURE 30 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011 (%)	150
FIGURE 31 MANUFACTURERS/PROCESSORS' MARKET SHARES OF HUMAN VACCINE SALES, 2011 (%)	158
FIGURE 32 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2010-2012 (\$ MILLIONS)	162
FIGURE 33 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 (\$ MILLIONS)	165
FIGURE 34 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2010-2017 (\$ MILLIONS)	167
FIGURE 35 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2010-2017 (\$ MILLIONS)	170
FIGURE 36 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	171
FIGURE 37 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011 (%)	172
FIGURE 38 GLOBAL SALES OF ANIMAL VACCINES BY REGION, 2010-2017 (\$ MILLIONS)	175
FIGURE 39 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%)	176
FIGURE 40 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE SALES, 2011 (%)	180
FIGURE 41 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR, 2010-2012 (NO.)	183
FIGURE 42 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE, 2010-2012 (NO.)	184
FIGURE 43 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	185
FIGURE 44 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	187
FIGURE 45 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	189
FIGURE 46 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	190
FIGURE 47 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	190
FIGURE 48 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	191
FIGURE 49 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	193
FIGURE 50 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	193
FIGURE 51 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	195
FIGURE 52 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	196
FIGURE 53 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	197
FIGURE 54 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	199

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 55 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (NO.)	200
FIGURE 56 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012 (%)	202
FIGURE 57 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY COMPANY, 2010-2012 (NO.)	203
FIGURE 58 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY COMPANY, 2010-2012 (NO.)	204
FIGURE 59 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY, 2010-2012 (NO.)	206
FIGURE 60 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY, 2010-2012 (NO.)	207
FIGURE 61 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY COMPANY, 2010-2012 (NO.)	208
FIGURE 62 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY COMPANY, 2010-2012 (NO.)	210
FIGURE 63 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	212
FIGURE 64 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	213
FIGURE 65 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	214
FIGURE 66 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	215
FIGURE 67 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	216
FIGURE 68 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	217
FIGURE 69 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE TYPE, 2010-2012 (NO.)	218